Showing results (141-150 of 259) with videos related to

Sort By:
Pageof 26
Biochemical Pharmacology|May 12, 2009
Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell linesSilvia La Monica, Maricla Galetti, Roberta R Alfieri, et al.
Breast Cancer Research : BCR|February 5, 2011
The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifenStephen B Fox, Daniele Generali, Alfredo Berruti, et al.
Journal of Clinical Medicine|June 10, 2022
Cytokine Profiles as Potential Prognostic and Therapeutic Markers in SARS-CoV-2-Induced ARDSFrancesco Salton, Paola Confalonieri, Giuseppina Campisciano, et al.
Future Oncology (London, England)|June 22, 2016
A Phase II study of olaparib in breast cancer patients: biological evaluation from a 'window of opportunity' trialGiandomenico Roviello, Manuela Milani, Angela Gobbi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2007
Regulation of hepatocyte growth factor activator inhibitor 2 by hypoxia in breast cancerDaniele Generali, Stephen B Fox, Alfredo Berruti, et al.
Annals of Surgical Oncology|September 12, 2012
Comparison of molecular subtyping with BluePrint, MammaPrint, and TargetPrint to local clinical subtyping in breast cancer patientsBichlien Nguyen, Pino G Cusumano, Kenneth Deck, et al.
Oncotarget|June 7, 2018
Platinum sensitivity and DNA repair in a recently established panel of patient-derived ovarian carcinoma xenograftsFederica Guffanti, Maddalena Fratelli, Monica Ganzinelli, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|August 27, 2015
Breast cancer circulating biomarkers: advantages, drawbacks, and new insightsAndrea Ravelli, James M Reuben, Francesco Lanza, et al.
European Journal of Endocrinology|December 23, 2011
Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinomaAlfredo Berruti, Paola Sperone, Anna Ferrero, et al.
The Oncologist|December 14, 2024
Identifying the best treatment choice for relapsing/refractory glioblastoma: a systematic review with multiple Bayesian network meta-analysesFrancesco Schettini, Estela Pineda, Andrea Rocca, et al.
Pageof 26